TY - JOUR
T1 - Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease
AU - Kahrilas, Peter J.
AU - Miner, Philip
AU - Johanson, John
AU - Mao, Lian
AU - Jokubaitis, Leonard
AU - Sloan, Sheldon
N1 - Funding Information:
Supported by Eisai Inc., Teaneck, New Jersey, and Janssen Pharma-ceutica Inc., Titusville, New Jersey.
PY - 2005/11
Y1 - 2005/11
N2 - The purpose of this study was to assess the rapidity of symptom relief and 4-week efficacy of rabeprazole 20 mg in patients with moderately severe nonerosive gastroesophageal reflux disease. Data were analyzed from 2 similarly designed, double-blind, placebo-controlled, multicenter, U.S. trials. After a 2-week placebo run-in period, patients (N = 261) were randomized to 4 weeks of rabeprazole 20 mg once daily or placebo. Patients kept symptom diaries and scored symptom severity. Median time to first 24-hour heartburn-free interval was 3.5 days for the rabeprazole group compared with 19.5 days for the placebo group (P ≤ .0002). Complete heartburn relief at week 4 was 32% with rabeprazole and 3.8% with placebo (P ≤ .001). Rabeprazole also significantly improved other GERD-associated symptoms (e.g., regurgitation, belching, early satiety) by week 4 compared with placebo (P ≤ .05). Rabeprazole provides fast and potent relief from heartburn and other symptoms of nonerosive gastroesophageal reflux disease.
AB - The purpose of this study was to assess the rapidity of symptom relief and 4-week efficacy of rabeprazole 20 mg in patients with moderately severe nonerosive gastroesophageal reflux disease. Data were analyzed from 2 similarly designed, double-blind, placebo-controlled, multicenter, U.S. trials. After a 2-week placebo run-in period, patients (N = 261) were randomized to 4 weeks of rabeprazole 20 mg once daily or placebo. Patients kept symptom diaries and scored symptom severity. Median time to first 24-hour heartburn-free interval was 3.5 days for the rabeprazole group compared with 19.5 days for the placebo group (P ≤ .0002). Complete heartburn relief at week 4 was 32% with rabeprazole and 3.8% with placebo (P ≤ .001). Rabeprazole also significantly improved other GERD-associated symptoms (e.g., regurgitation, belching, early satiety) by week 4 compared with placebo (P ≤ .05). Rabeprazole provides fast and potent relief from heartburn and other symptoms of nonerosive gastroesophageal reflux disease.
KW - Gastroesophageal reflux disease symptoms
KW - Nonerosive gastroesophageal reflux disease
KW - Proton pump inhibitor
KW - Rabeprazole
UR - http://www.scopus.com/inward/record.url?scp=27144502406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27144502406&partnerID=8YFLogxK
U2 - 10.1007/s10620-005-3000-3
DO - 10.1007/s10620-005-3000-3
M3 - Article
C2 - 16240208
AN - SCOPUS:27144502406
VL - 50
SP - 2009
EP - 2018
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
SN - 0163-2116
IS - 11
ER -